Market Overview:
The global neuroprotection market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as increasing incidence of neurological disorders, rising geriatric population, and growing awareness about neuroprotection therapies. The global neuroprotection market is segmented on the basis of type into free anti-inflammatory agents, radical trapping agents (antioxidants), apoptosis inhibitors, glutamate antagonists (anti-excitotoxic agents), neurotrophic factors (NTFs), stimulants, metal ion chelators, and others. The free anti-inflammatory agents segment is expected to dominate the market in 2018 owing to its high usage in various neurological disorders. However, the glutamate antagonists (anti-excitotoxic agents) segment is projected to grow at a highest CAGR during the forecast period due to increasing prevalence of excitotoxicity mediated neurological disorders. On the basis of application, the global neuroprotection market is divided into prevention and treatment segments. The prevention segment accounted for majority share of the global neuroprotection market in 2017 and it is projected to maintain its dominance during forecast period owing rising awareness about preventive measures for various neurological diseases among people across globe . However ,the treatment segmentis anticipatedto witness highest growth rate over next decade duegrowing demand for better therapeutic optionsfor managing Neurological Disorders .
Product Definition:
Neuroprotection is the preservation of neurons from damage. It can be done through pharmacological or non-pharmacological means. The importance of neuroprotection lies in the fact that brain damage can lead to a host of neurological problems, including cognitive decline, dementia, and even death.
Free Anti-Inflammatory Agents:
Free anti-inflammatory agents are chemicals that reduce or eliminate inflammation without any side effects. Neuroinflammation is the brain inflammation caused due to a number of reasons such as infection, stroke, trauma and autoimmune diseases. The free anti-inflammatory agents act by blocking the production of cytokines which cause neurodegenerative disorders like multiple sclerosis, Alzheimer’s disease and Parkinson’s disease etc.
Radical Trapping Agents (Antioxidants):
Radical trapping agents are natural or synthetic compounds that prevent the oxidation of other antioxidants in the cell. They can be used as both antioxidants and radical trap agents. The most common traps include BHA, BHT, propyl gallates, and tocopheryl acetate among others.
Application Insights:
The prevention segment dominated the global market in 2017. The application of neuroprotective agents before, during and after brain injuries is anticipated to gain traction over the coming years owing to its ability to prevent cell death caused due to oxygen and glucose deprivation as well as glutamate excitotoxicity.
Glutamate-based drugs are used for treating a variety of conditions such as traumatic brain injury, Parkinson¢â‚¬â„¢s disease, Alzheimer¢â‚¬â„¢s disease and multiple sclerosis. However, these drugs have severe side effects which limit their use in clinical trials. This has led researchers towards developing new molecules with fewer side effects that can act as effective neuroprotectants against various neurological disorders.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period owing to increasing cases of neurodegenerative diseases, presence of key players, and availability of advanced therapeutics. In addition, rising awareness about neurological disorders and supportive government initiatives are anticipated to drive growth in this region.
Asia Pacific is estimated to witness lucrative growth over the forecast period due to factors such as improving healthcare infrastructure & reimbursement policies; growing economy; increase in disposable income coupled with rise in consumerism resulting from rapid urbanization & industrialization which has leded into an increased demand for anti-inflammatory drugs among patients suffering from neurodegenerative diseases such as Parkinson’s disease (PD) or Alzheimer's disease (AD). Moreover, a high prevalence rate for diabetes coupled with an aging population will further boost regional market growth over the coming years.
Growth Factors:
- Increasing incidence of neurological disorders: The global prevalence of neurological disorders is increasing at an alarming rate. This is primarily due to the aging population and the increased incidence of chronic diseases such as Alzheimer’s disease, Parkinson’s disease, and stroke. The Neuroprotection market is expected to grow significantly in response to this growing demand for neuroprotective therapies.
- Advances in neuroscience research: There has been a significant advancement in neuroscience research in recent years, which has led to the identification of new neuroprotective targets and molecules. This is providing a boost to the development of novel neuroprotective therapies and driving growth in the Neuroprotection market.
- Growing awareness about neurological disorders: There is a growing awareness among people about various neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and stroke. This is helping to create a larger pool of potential patients for neuroprotective therapies and driving growth in the Neuroprotection market .
Scope Of The Report
Report Attributes
Report Details
Report Title
Neuroprotection Market Research Report
By Type
Free Anti-Inflammatory Agents, Radical Trapping Agents (Antioxidants), Apoptosis Inhibitors, Glutamate Antagonists (Anti-Excitotoxic Agents), Neurotrophic Factors (NTFs), Stimulants, Metal Ion Chelators, Others
By Application
Prevention, Treatment
By Companies
F. Hoffmann-La Roche, Eli Lilly and Company, Daiichi Sankyo Company, Allergan, Novartis, AstraZeneca, Dr. Reddy's Laboratories, Astrocyte Pharmaceuticals, Teva Pharmaceutical Industries, Biogen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Neuroprotection Market Report Segments:
The global Neuroprotection market is segmented on the basis of:
Types
Free Anti-Inflammatory Agents, Radical Trapping Agents (Antioxidants), Apoptosis Inhibitors, Glutamate Antagonists (Anti-Excitotoxic Agents), Neurotrophic Factors (NTFs), Stimulants, Metal Ion Chelators, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Prevention, Treatment
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- F. Hoffmann-La Roche
- Eli Lilly and Company
- Daiichi Sankyo Company
- Allergan
- Novartis
- AstraZeneca
- Dr. Reddy's Laboratories
- Astrocyte Pharmaceuticals
- Teva Pharmaceutical Industries
- Biogen
Highlights of The Neuroprotection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Free Anti-Inflammatory Agents
- Radical Trapping Agents (Antioxidants)
- Apoptosis Inhibitors
- Glutamate Antagonists (Anti-Excitotoxic Agents)
- Neurotrophic Factors (NTFs)
- Stimulants
- Metal Ion Chelators
- Others
- By Application:
- Prevention
- Treatment
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Neuroprotection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Neuroprotection is the umbrella term for a variety of interventions that aim to protect the brain from damage. These interventions can take many different forms, including pharmacological, non-pharmacological, and surgical treatments.
Some of the major players in the neuroprotection market are F. Hoffmann-La Roche, Eli Lilly and Company, Daiichi Sankyo Company, Allergan, Novartis, AstraZeneca, Dr. Reddy's Laboratories, Astrocyte Pharmaceuticals, Teva Pharmaceutical Industries, Biogen.
The neuroprotection market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Neuroprotection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Neuroprotection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Neuroprotection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Neuroprotection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Neuroprotection Market Size & Forecast, 2018-2028
4.5.1 Neuroprotection Market Size and Y-o-Y Growth
4.5.2 Neuroprotection Market Absolute $ Opportunity
Chapter 5 Global Neuroprotection Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Neuroprotection Market Size Forecast by Type
5.2.1 Free Anti-Inflammatory Agents
5.2.2 Radical Trapping Agents (Antioxidants)
5.2.3 Apoptosis Inhibitors
5.2.4 Glutamate Antagonists (Anti-Excitotoxic Agents)
5.2.5 Neurotrophic Factors (NTFs)
5.2.6 Stimulants
5.2.7 Metal Ion Chelators
5.2.8 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Neuroprotection Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Neuroprotection Market Size Forecast by Applications
6.2.1 Prevention
6.2.2 Treatment
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Neuroprotection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Neuroprotection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Neuroprotection Analysis and Forecast
9.1 Introduction
9.2 North America Neuroprotection Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Neuroprotection Market Size Forecast by Type
9.6.1 Free Anti-Inflammatory Agents
9.6.2 Radical Trapping Agents (Antioxidants)
9.6.3 Apoptosis Inhibitors
9.6.4 Glutamate Antagonists (Anti-Excitotoxic Agents)
9.6.5 Neurotrophic Factors (NTFs)
9.6.6 Stimulants
9.6.7 Metal Ion Chelators
9.6.8 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Neuroprotection Market Size Forecast by Applications
9.10.1 Prevention
9.10.2 Treatment
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Neuroprotection Analysis and Forecast
10.1 Introduction
10.2 Europe Neuroprotection Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Neuroprotection Market Size Forecast by Type
10.6.1 Free Anti-Inflammatory Agents
10.6.2 Radical Trapping Agents (Antioxidants)
10.6.3 Apoptosis Inhibitors
10.6.4 Glutamate Antagonists (Anti-Excitotoxic Agents)
10.6.5 Neurotrophic Factors (NTFs)
10.6.6 Stimulants
10.6.7 Metal Ion Chelators
10.6.8 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Neuroprotection Market Size Forecast by Applications
10.10.1 Prevention
10.10.2 Treatment
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Neuroprotection Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Neuroprotection Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Neuroprotection Market Size Forecast by Type
11.6.1 Free Anti-Inflammatory Agents
11.6.2 Radical Trapping Agents (Antioxidants)
11.6.3 Apoptosis Inhibitors
11.6.4 Glutamate Antagonists (Anti-Excitotoxic Agents)
11.6.5 Neurotrophic Factors (NTFs)
11.6.6 Stimulants
11.6.7 Metal Ion Chelators
11.6.8 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Neuroprotection Market Size Forecast by Applications
11.10.1 Prevention
11.10.2 Treatment
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Neuroprotection Analysis and Forecast
12.1 Introduction
12.2 Latin America Neuroprotection Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Neuroprotection Market Size Forecast by Type
12.6.1 Free Anti-Inflammatory Agents
12.6.2 Radical Trapping Agents (Antioxidants)
12.6.3 Apoptosis Inhibitors
12.6.4 Glutamate Antagonists (Anti-Excitotoxic Agents)
12.6.5 Neurotrophic Factors (NTFs)
12.6.6 Stimulants
12.6.7 Metal Ion Chelators
12.6.8 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Neuroprotection Market Size Forecast by Applications
12.10.1 Prevention
12.10.2 Treatment
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Neuroprotection Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Neuroprotection Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Neuroprotection Market Size Forecast by Type
13.6.1 Free Anti-Inflammatory Agents
13.6.2 Radical Trapping Agents (Antioxidants)
13.6.3 Apoptosis Inhibitors
13.6.4 Glutamate Antagonists (Anti-Excitotoxic Agents)
13.6.5 Neurotrophic Factors (NTFs)
13.6.6 Stimulants
13.6.7 Metal Ion Chelators
13.6.8 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Neuroprotection Market Size Forecast by Applications
13.10.1 Prevention
13.10.2 Treatment
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Neuroprotection Market: Competitive Dashboard
14.2 Global Neuroprotection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 F. Hoffmann-La Roche
14.3.2 Eli Lilly and Company
14.3.3 Daiichi Sankyo Company
14.3.4 Allergan
14.3.5 Novartis
14.3.6 AstraZeneca
14.3.7 Dr. Reddy's Laboratories
14.3.8 Astrocyte Pharmaceuticals
14.3.9 Teva Pharmaceutical Industries
14.3.10 Biogen
